Intended for UK healthcare professionals


Flu just met its
genetic match

Introducing Supemtek
Recombinant technology
Comparison versus standard influenza vaccines


Supemtek is included in latest 2022/23 Joint Committee on Vaccination and Immunisation (JCVI) recommendations for all eligible adult cohorts.1

Click here to download more information on Supemtek


Target influenza with Supemtek (Quadrivalent Influenza Vaccine, recombinant prepared in cell-culture), the first recombinant influenza vaccine in Europe. Supemtek is manufactured to offer an exact genetic match to the World Health Organization (WHO)-predicted viral strains.2,3

Supemtek Prescribing Information


Supemtek quadrivalent influenza vaccine is indicated for active immunisation for the prevention of influenza disease in adults.2


Click here to order and manage your vaccines online with our e-ordering and e-accounting site.

Visit Vaxishop

Supemtek's clinical data and safety profile

Watch the video to find out more about Supemtek's clinical data
and safety profile.

Watch Now


A recent, self-controlled case series study showed that adults aged ≥40 years (median age of
68 years), without a history of heart attack or stroke, were at an increased risk of severe cardiovascular complications in the 1–3 days following a confirmed influenza infection.*4

Patients were at a 10x increased risk of a first heart attack and 8x increased risk of a first stroke.*4

Each year in the UK, influenza vaccination could help to reduce the number of influenza cases
and influenza-related premature deaths.5



Recombinant technology eliminates the possibility of adaptation or mutation by replicating only the haemagglutinin (HA) antigen direct from a genetic sequence. The resulting antigens are an exact genetic match to the target strain HA antigen.3,6

Find out more about the recombinant technology used to manufacture Supemtek here

Discover more


Supemtek contains 3x more HA antigen (45 mcg versus 15 mcg) per strain, compared with cell-
and egg-based standard-dose quadrivalent influenza vaccines.3


Supemtek demonstrated 30% greater relative efficacy (1% absolute efficacy) versus standard-dose egg-based quadrivalent inactivated influenza vaccine (QIVe), in preventing confirmed cases of influenza-like illness in adults ≥50 years of age, with respective influenza attack rates of
2.2% and 3.2 %.†3

Find out more about the clinical data for Supemtek here

Discover more


Supemtek demonstrated a comparable safety profile to standard-dose egg-based QIVe.3,7

Find out more about the safety profile of Supemtek here

Discover more


Randomised controlled trials support the efficacy and safety of Supemtek for active immunisation for the prevention of influenza disease in adults ≥18 years of age.3,7

Find out more about the clinical development of Supemtek here

Discover more


Results from a European Centre for Disease Prevention and Control (ECDC) systematic literature review to assess the efficacy, effectiveness and safety of enhanced influenza vaccines (versus standard-dose or placebo) for the prevention of laboratory-confirmed influenza in adults ≥18 years of age suggested that Supemtek may offer ”better protection than no vaccination, or standard influenza vaccines.”(QIVe)8

Find out more about the results of the review here

Discover more

*As measured by age- and season-adjusted incidence ratios for myocardial infarction (n=1,227) or stroke (n=762) in adults aged 40 years or older, in the 1-3 days following a laboratory-confirmed influenza infection. Adjusted IRs were 9.80 (95% CI: 2.37, 40.5) and 7.82 (95% CI: 1.07, 56.9) for myocardial infarction and stroke, respectively.4

As measured by relative vaccine efficacy (rVE) in adults aged 50+ years, randomised 1:1 to receive single dose of Supemtek (n=4,303) or standard-dose egg-based QIVe (n=4,301) during the 2014/15 influenza season (95% CI: 10, 47 p=0.006). Influenza attack rates were 2.2.% and 3.2% for Supemtek and standard-dose QIVe, respectively. The lower bound (LB) of the 95% confidence interval met the pre-specified, exploratory criterion for superior rVE LB >9%. Primary endpoint: rVE against reverse transcription polymerase chain reaction-confirmed, protocol-defined, influenza-like illness caused by any influenza strain starting 14 days or more after vaccination.3

Vaccination Live

Webinar and face-to-face educational promotional meetings with sessions on flu and travel vaccination.

Discover More

CI, confidence interval; ECDC, European Centre for Disease Prevention and Control; HA, haemagglutinin; JCVI, Joint Committee on Vaccination and Immunisation; LB, lower bound; QIVe, quadrivalent inactivated influenza vaccine; rVE, relative vaccine efficacy; WHO, World Health Organization.

  1. Joint Committee on Vaccination and Immunisation (JCVI). Advice on influenza vaccines for 2022/23. [Last accessed January 2022].
  2. Supemtek Summary of Product Characteristics.
    [Last accessed January 2022].
  3. Dunkle LM, et al. N Engl J Med. 2017;376:2427–36.
  4. Warren-Gash C, et al. Eur Resp J. 2018;51:1701794.
  5. Franklin B and Hochlaf D. An economic analysis of flu vaccination. [Last accessed January 2022].
  6. Centers for Disease Control and Prevention. How influenza (flu) vaccines are made. [Last accessed January 2022].
  7. Dunkle LM, et al. J Infect Dis. 2017;216:1219–26.
  8. ECDC (2020) Systematic review of the efficacy, effectiveness, and safety of newer and enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over. [Last accessed January 2022].

Date of preparation: January 2022 | MAT-GB-2003349(v4.0)